Treatment of Disseminated Varicella-Zoster Virus (VZV)

Introduction to Treatment

The Infectious Diseases Society of America recommends intravenous acyclovir 10 mg/kg every 8 hours as the treatment of choice for disseminated VZV infection, which should be initiated immediately due to the high mortality risk in immunocompromised patients 1, 2, 3

The American College of Physicians suggests starting IV acyclovir without delay at 10 mg/kg every 8 hours, with some sources suggesting a 5-10 mg/kg range, but 10 mg/kg is preferred for disseminated disease 1, 2, 3
Disseminated VZV lesions characteristically begin on the face and trunk, then evolve peripherally, with lesions in varied stages of progression appearing simultaneously 2, 3
The Centers for Disease Control and Prevention advises against using oral antivirals (valacyclovir, famciclovir, or oral acyclovir) for suspected disseminated disease, reserving oral therapy for mild cases in otherwise healthy hosts or to complete therapy after clinical response to IV treatment 2, 3

The Infectious Diseases Society of America recommends continuing IV acyclovir until clinical improvement occurs, typically 7-14 days minimum, then considering switching to oral therapy to complete the course 3
In immunocompromised patients, lesions may continue to develop over 7-14 days and heal more slowly, requiring prolonged IV treatment 2, 3

The American Medical Association suggests that if the patient is on immunosuppressive medications, they should be temporarily reduced or discontinued while maintaining antiviral therapy 5, 4

Blood VZV-DNA PCR may help establish the diagnosis of disseminated infection, particularly when presentation is atypical or precedes rash appearance 1

The National Kidney Foundation recommends adjusting the acyclovir dose for renal impairment and monitoring renal function frequently, as acyclovir can be nephrotoxic 6
Ensuring adequate hydration is crucial to prevent acyclovir-induced crystalline nephropathy 6

The American College of Emergency Physicians advises against delaying treatment while waiting for confirmatory testing, instead initiating IV acyclovir based on clinical suspicion alone 1, 4
The Infectious Diseases Society of America warns against undertreating with oral antivirals, which is a critical error in disseminated or potentially disseminated disease 2, 3, 5